Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, prospective phase II clinical trial aimed at
exploring and evaluating the efficacy of dalpiciclib combined with AI in neoadjuvant
treatment for ER strong positive（ER≥50%），HER2-negative, Ki-67≤20%,T1-3N1M0 postmenopausal
breast cancer. The primary objectives are to demonstrate non-inferiority in efficacy compared
to chemotherapy and to assess its superior safety profile.